.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKesson
US Army
Farmers Insurance
Baxter
Healthtrust
Cantor Fitzgerald
Express Scripts
US Department of Justice

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms
Abstract: An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin\'s lymphoma.
Inventor(s): Morariu; Rodica (Paris, FR)
Assignee: Sanofi (Paris, FR)
Application Number:14/117,806
Patent Claims:1. A method of treating CD19+ B-cell malignancies symptom in a human patient in need thereof, said method comprising a) administering to said patient an initial dose of 55 mg/m.sup.2 of an anti-CD19 maytansinoid immunoconjugate, b) administering to the patient at least 3 subsequent doses of 55 mg/m.sup.2 of the anti-CD19 maytansinoid immunoconjugate separated in time from each other by about one week, and c) administering to the patient at least 3 further subsequent doses of 55 mg/m.sup.2 of the anti-CD19 maytansinoid immunoconjugate separated in time from each other by about two weeks, wherein said anti-CD19 maytansinoid immunoconjugate comprises an antibody that specifically binds to a CD19 antigen comprising: a) a heavy chain CDR1 comprising SNWMH (SEQ ID NO.4); a heavy chain CDR2 comprising EIDPSDSYTN (SEQ ID NO.5); and a heavy chain CDR3 comprising GSNPYYYAMDY (SEQ ID NO.6); and b) a light chain CDR1 comprising SASSGVNYMH (SEQ ID NO:1); a light chain CDR2 comprising DTSKLAS (SEQ ID NO:2); and a light chain CDR3 comprising HQRGSYT (SEQ ID NO:3), wherein the maytansinoid is DM4; and wherein the antibody is conjugated to DM4 through N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) linker.

2. The method according to claim 1, wherein the method minimizes eye related adverse events.

3. The method according to claim 2, wherein the occurrence of all grades of eye related adverse events is below 40%.

4. The method according to claim 2, wherein the occurrence of grade 3 or 4 eye related adverse events is below 13%.

5. The method according to claim 1, wherein said CD19+ B-cell malignancies symptom is a leukemia or a lymphoma.

6. The method according to claim 5, wherein said lymphoma is Non-Hodgkin's lymphoma (NHL).

7. The method according to claim 5, wherein said leukemia is Acute lymphoblastic leukemia (ALL).

8. The method according to claim 6, wherein said Non-Hodgkin's lymphoma is Diffuse Large B-cell lymphoma (DLBCL), a follicular lymphoma (FL), a Mantle cell lymphoma (MCL), a Marginal zone lymphoma (MZL), a Small lymphocytic lymphoma (SLL), or a Waldenstrom macroglobulinemia (WM).

9. The method according to claim 6, wherein said NHL is a relapsed or refractory NHL.

10. The method according to claim 6, wherein said NHL is a NHL expressing CD19.

11. The method according to claim 6, wherein said patient has already been treated for the NHL.

12. The method according to claim 6, wherein said patient has failed rituximab therapy.

13. The method according to claim 6, wherein said NHL is rituximab resistant.

14. The method according to claim 6, wherein said patient has received an autologous or allogeneic stem cell transplant.

15. The method according to claim 1, wherein the anti-CD19 maytansinoid immunoconjugate is administered intravenously.

16. The method according to claim 1, wherein the anti-CD19 maytansinoid immunoconjugate comprises an huB4 antibody conjugated to DM4 through an SPDB linker.

17. The method according to claim 1, wherein the anti-CD19 maytansinoid immunoconjugate has the following formula: ##STR00002##

18. The method according to claim 1, wherein the antibody comprises a light chain having the sequence of SEQ ID NO.7 and a heavy chain having the sequence of SEQ ID NO.8.

19. The method according to claim 16, wherein 3.5 molecules of DM4 are bound through the SPDB linker to each huB4 antibody molecule.

20. A method of treating CD19+ B-cell malignancies symptom in a human patient in need thereof, wherein the method comprises administering to the patient 4 doses of 55 mg/m.sup.2 of an anti-CD19 maytansinoid immunoconjugate separated in time from each other by one week, and administering to the patient 4 subsequent doses of 55 mg/m.sup.2 of the anti-CD19 maytansinoid immunoconjugate separated in time from each other by two weeks, wherein said anti-CD19 maytansinoid immunoconjugate comprises an antibody that specifically binds to a CD19 antigen comprising: a) a heavy chain CDR1 comprising SNWMH (SEQ ID NO.4); a heavy chain CDR2 comprising EIDPSDSYTN (SEQ ID NO.5); and a heavy chain CDR3 comprising GSNPYYYAMDY (SEQ ID NO.6); and b) a light chain CDR1 comprising SASSGVNYMH (SEQ ID NO:1); a light chain CDR2 comprising DTSKLAS (SEQ ID NO:2); and a light chain CDR3 comprising HQRGSYT (SEQ ID NO:3), wherein the maytansinoid is DM4; and wherein the antibody is conjugated to DM4 through N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) linker.

21. The method of claim 20, wherein the antibody comprises a light chain having the sequence of SEQ ID NO.7 and a heavy chain having the sequence of SEQ ID NO.8.

22. The method of claim 20, wherein the antibody is HuB4 antibody.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11290232May 17, 2011
PCT Information
PCT FiledMay 16, 2012PCT Application Number:PCT/EP2012/059141
PCT Publication Date:November 22, 2012PCT Publication Number: WO2012/156455

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Sanofi (Paris, FR) Morariu; Rodica (Paris, FR) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Argentina086412Dec 11, 2013
Australia2012258254Apr 21, 2016
Australia2012258254May 02, 2013
Australia2016206317Aug 11, 2016
Brazil112013029330Nov 29, 2016
Canada2835738Nov 22, 2012
China103547596Jan 29, 2014
Colombia6821893Dec 31, 2013
Costa Rica20130593Jan 09, 2014
Dominican RepublicP2013000260Jan 31, 2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Queensland Health
McKinsey
Novartis
Covington
Chubb
Citi
QuintilesIMS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot